Slide 1: Investor and Analyst Conference Call Q1 2019
Investor and Analyst Conference Call Q1 2019 Grünwald, May 21, 2019
Slide 2: Agenda
Agenda 1. Overview 2. Financial figures Q1 2019 3. Outlook FY 2019 4. Q&A
Slide 3: Agenda: Overview
Agenda 1. Overview 2. Financial figures Q1 2019 3. Outlook FY 2019 4. Q&A
Slide 4: Dermapharm – Pharmaceutical excellence "Made in Germany"
Dermapharm – Pharmaceutical excellence “Made in Germany” Dermapharm’s integrated business model… …results in attractive financials… Group revenues Q1 2019 in € million Total: 163.6 20.6 Herbal extracts Revenue split 58.5 84.4 Parallel import business Branded pharmaceuticals and other healthcare prod
Slide 5: Dermapharm – Highlights Q1 2019 (1)
Dermapharm – Highlights Q1 2019 (1) Successful product development ▪ All ongoing development projects on track ▪ News about important products, e.g.: ▪ Dekristol 20.000 – News from authorities ▪ Hygroton 25 mg and 50 mg – Diuretic of first choice after “Dear Doctor Letter” ▪ Myopridin via Trommsdorf
Slide 6: Dermapharm – Highlights Q1 2019 (2)
Dermapharm – Highlights Q1 2019 (2) Ongoing Internationali- investments in M&A activities sation further growth ▪ mibe GmbH Arzneimittel in Brehna ▪ Acquisition and ongoing ▪ Launch of further products in UK and (Germany) integration of Euromed and thereby Italy expansion of the portfolio with new ▪
Slide 7: Agenda: Financial figures Q1 2019
Agenda 1. Overview 2. Financial figures Q1 2019 3. Outlook FY 2019 4. Q&A
Slide 8: Dermapharm Group Revenue – Growth from Branded Pharmaceuticals and new segment Herbal Extracts
Dermapharm Group Revenue – Growth from Branded Pharmaceuticals and new segment Herbal Extracts Dermapharm’s revenue development Dermapharm Group Q1 2018 vs Q1 2019 €m, YoY growth (%) ▪ Significant revenue growth of 19.0% to € 163.6 million ▪ Main growth drivers: 163.6 ▪ Successful acquisition and in
Slide 9: Dermapharm Group EBITDA – Increase due to successful acquisition
Dermapharm Group EBITDA – Increase due to successful acquisition Dermapharm’s EBITDA(1) development Dermapharm Group Q1 2018 vs Q1 2019 €m, YoY growth (%) ▪ EBITDA up by 20.7% to € 43.7 million (adjusted) and 14.6% to € 40.7 million (unadjusted) EBITDA margin ▪ Strong EBITDA margin of 26.7% (adjuste
Slide 10: Earnings before tax (EBT) – Reflecting investments in future growth
Earnings before tax (EBT) – Reflecting investments in future growth Dermapharm’s EBT(1) development Comments Q1 2018 vs Q1 2019 €m, YoY growth (%) ▪ EBT decreased by 9.9% to € 27.2 million (unadjusted) resulting in a margin of 16.6% ▪ Depreciations and amortization increased by € 6.9 million due to
Slide 11: Cash flows and cash conversion – Reflecting strong dedication to future growth
Cash flows and cash conversion – Reflecting strong dedication to future growth Cash flow and cash conversion(1) Comments in €m / in % of group EBITDA ▪ CF from operating activities down due to income tax payments and a decrease in active working capital Cash 167.1% 38.4% ▪ CF from investing activiti
Slide 12: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 31 March 2019 Comments in €m ▪ Total assets increased to € 961.8 million ▪ Non-current assets increased mainly due to the increase in intangible assets, goodwill and property, plant and equipment 961.8 961.8 ▪ Current assets decreased mainly due
Slide 13: Agenda: Outlook FY 2019
Agenda 1. Overview 2. Financial figures Q1 2019 3. Outlook FY 2019 4. Q&A
Slide 14: Growth strategy on track and conforming guidance 2019
Growth strategy on track and conforming guidance 2019 Revenues EBITDA 2019 +14% to +19% +17% to +22% 2019 (adjusted) ▪ over previous year (2018: € 572 million) ▪ over previous year (2018: € 143.4 million (adjusted)) “Growth rates are based on organic growth, new launches of in-house developments and
Slide 15: Investors' and Analysts' Conference Call – Q&A
Investors’ and Analysts’ Conference Call FY 2018 Q&A
Slide 16: Investor contact
Investor contact Britta Hamberger Investor Relations Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233